142 related articles for article (PubMed ID: 25250422)
1. Correction to the paper, "Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography".
Retina; 2014 May; 34(5):e15. PubMed ID: 25250422
[No Abstract] [Full Text] [Related]
2. Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography.
Spaide RF
Retina; 2011 May; 31(5):829-37. PubMed ID: 21487338
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion.
Spaide RF
Retina; 2013 Jan; 33(1):56-62. PubMed ID: 23269405
[TBL] [Abstract][Full Text] [Related]
4. Analysis of retinal nonperfusion using depth-integrated optical coherence tomography images in eyes with branch retinal vein occlusion.
Sakimoto S; Gomi F; Sakaguchi H; Akiba M; Kamei M; Nishida K
Invest Ophthalmol Vis Sci; 2015 Jan; 56(1):640-6. PubMed ID: 25574041
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
7. Progressive retinal nonperfusion in ischemic central retinal vein occlusion.
Wykoff CC; Brown DM; Croft DE; Major JC; Wong TP
Retina; 2015 Jan; 35(1):43-7. PubMed ID: 25102193
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
11. Multifocal electrophysiologic findings after intravitreal bevacizumab (avastin) treatment.
Torres-Soriano ME; Cubas-Lorenzo V; García-Aguirre G; Hernández-Rojas M; Kon-Jara V; Díaz-Rubio J; Fromow-Guerra J; Quiroz-Mercado H; Jiménez-Sierra JM
Retina; 2012 May; 32(5):972-6. PubMed ID: 22105506
[TBL] [Abstract][Full Text] [Related]
12. Cat scratch disease associated with retinal vein occlusion.
Rubinov A; Blumenthal EZ; Beiran I
Isr Med Assoc J; 2014 Aug; 16(8):522-3. PubMed ID: 25269350
[No Abstract] [Full Text] [Related]
13. Optical coherence tomography angiography wide-field montage in branch retinal vein occlusion before and after anti-vascular endothelial-derived growth factor injection.
Chung CY; Li KKW
Int Ophthalmol; 2018 Jun; 38(3):1305-1307. PubMed ID: 28536764
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
16. Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion.
Terui T; Kondo M; Sugita T; Ito Y; Kondo N; Ota I; Miyake K; Terasaki H
Retina; 2011 Jun; 31(6):1068-74. PubMed ID: 21451440
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
[TBL] [Abstract][Full Text] [Related]
20. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
